Research location
Bełchatów
Poland
Advertisement
Research activity in Bełchatów
PolandCureCurrent currently publishes aggregate city-level research activity for this location: 40 trials and 40 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Bełchatów
40 linked trials · page 1 of 1EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240 · 2025-06-19 · 1 site observation
RECRUITING
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06966401 · 2025-04-16 · 1 site observation
RECRUITING
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation
TERMINATED
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)NCT05518149 · 2022-09-22 · 1 site observation
TERMINATED
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyNCT05455684 · 2022-06-22 · 1 site observation
COMPLETED
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyNCT05211947 · 2022-03-21 · 1 site observation
TERMINATED
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)NCT05203341 · 2022-02-21 · 1 site observation
COMPLETED
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT05061719 · 2021-10-08 · 1 site observation
COMPLETED
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT05061706 · 2021-09-30 · 1 site observation
COMPLETED
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)NCT04846881 · 2021-08-24 · 1 site observation
COMPLETED
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)NCT04509674 · 2020-12-16 · 1 site observation
COMPLETED
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyNCT04513912 · 2020-09-15 · 1 site observation
COMPLETED
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic TreatmentNCT04421456 · 2020-08-18 · 1 site observation
TERMINATED
Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus GlobalNCT04236609 · 2020-06-15 · 1 site observation
UNKNOWN
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentNCT04000009 · 2019-06-06 · 1 site observation
TERMINATED
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentNCT03968159 · 2019-04-25 · 1 site observation
COMPLETED
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant DepressionNCT03965858 · 2019-02-25 · 1 site observation
COMPLETED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of SchizophreniaNCT03896945 · 2019-02-15 · 1 site observation
TERMINATED
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With SchizophreniaNCT03793712 · 2018-12-27 · 1 site observation
TERMINATED
Effect of Lu AF35700 in Patients With Treatment-resistant SchizophreniaNCT02717195 · 2016-04-01 · 1 site observation
COMPLETED
An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive DisorderNCT02473289 · 2015-07-23 · 1 site observation
COMPLETED
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderNCT02161718 · 2014-05-01 · 1 site observation
COMPLETED
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyNCT01714713 · 2013-06-01 · 1 site observation
COMPLETED
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus TrialNCT01727726 · 2012-12-01 · 1 site observation
COMPLETED
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyNCT01716975 · 2012-10-01 · 1 site observation
COMPLETED
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With SchizophreniaNCT01515423 · 2012-05-01 · 1 site observation
COMPLETED
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)NCT01360866 · 2011-10-01 · 1 site observation
COMPLETED
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant TherapyNCT01437657 · 2011-10-01 · 1 site observation
COMPLETED
Safety and Efficacy of Zicronapine in Patients With SchizophreniaNCT01295372 · 2011-04-01 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)NCT01111565 · 2010-10-04 · 1 site observation
TERMINATED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderNCT01180400 · 2010-09-01 · 1 site observation
COMPLETED
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With SchizophreniaNCT01129882 · 2010-06-24 · 1 site observation
COMPLETED
A Study in Adult Patients With Major Depressive DisorderNCT00795821 · 2008-12-01 · 1 site observation
COMPLETED
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaNCT00731549 · 2008-12-01 · 1 site observation
COMPLETED
Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With SchizophreniaNCT00810667 · 2008-11-01 · 1 site observation
COMPLETED
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)NCT01078545 · 2008-09-01 · 1 site observation
COMPLETED
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaNCT00706654 · 2008-09-01 · 1 site observation
COMPLETED
A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and InsomniaNCT00435279 · 2007-06-01 · 1 site observation
COMPLETED
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With SchizophreniaNCT00589914 · 2007-03-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.